Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI PET to Predict T-DXd Response in HER2+ Breast Cancer Brain Metastases
NCT06797622Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in HER2-positive breast cancer and brain metastases, sponsored by Fudan University. Primary endpoint: Difference of baseline heterogeneity index at 6 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
HER2-positive breast cancerbrain metastases
Beyond the preview
Go deeper on NCT06797622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797622.